Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
OXiGENE is an international biopharmaceutical company developing a portfolio of products that focus primarily on combating cancer. The Company´s initial product development is based on proprietary DNA repair technology. The Company currently has three products in clinical development , including Neu-Sensamide , in pivotal Phase III clinical trials in patients with non-small cell lung cancer and a Phase I study in patients with glioblastoma ; Oxi-104 , a chemosensitizer in Phase I studies in patients with advanced stage cancers ; and Cordycepin , in Phase I studies in patients with leukemia. The Company is also developing a vascular targeting agent , Combretastatin A-4 prodrug. ( www.oxigene.com )
OXiGENE , Inc.
230 Third Avenue
Waltham, Massachusetts 02451
USA
Tel: (781) 547-5900
Fax: (781) 547-6800